HPS/PayMedix Secures $33 Million Investment
New growth equity investment, led by HLM Investment Partners, will accelerate growth of the PayMedix financing platform nationally
The funding comes at a time of notable growth for the company, as demand increases for its innovative healthcare payments platform to improve affordable access to healthcare nationwide.
"PayMedix is a highly effective platform that streamlines the payment experience for payors, providers, and members," said
The new term debt facility of
"As employers, providers, and payors look for alternative financing and payment solutions to deal with the affordability crisis in healthcare, demand for PayMedix has skyrocketed in the last year," said
About HLM Investment Partners
HLM Investment Partners is a leading healthcare investment firm, providing capital to innovative and category-defining healthcare technology and services companies. HLM works with leading growth-oriented healthcare companies that are improving the quality of healthcare while reducing overall costs. HLM has built an extensive network of talented investment professionals, deep strategic relationships and experienced industry veterans. Since its founding 40 years ago, HLM has invested more than
About HPS/PayMedix
PayMedix is transforming how people access, use, and pay for healthcare by simplifying and consolidating healthcare information and payments for consumers and providers. Through guaranteed payments to providers, the SuperEOB®, and complete interest-free financing for consumers, PayMedix is the only platform that unifies all stakeholders through a single system. PayMedix has processed over
View original content to download multimedia:https://www.prnewswire.com/news-releases/hpspaymedix-secures-33-million-investment-302659452.html
SOURCE HPS/PayMedix
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Corgi Insurance Launches Golden, a Dedicated Sports and Entertainment Insurance Vertical Built for the $600 Billion Sports Industry
- Lynk Pharmaceuticals Announces Completion of Patient Enrollment in Phase III Clinical Trial of Zemprocitinib for Ankylosing Spondylitis
- Clearside Biomedical, Inc. Completes Financial Restructuring and Emerges from Chapter 11 with Steel Partners as Plan Sponsor
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
Definitive AgreementSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share